Repligen

RGENNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$9.250 B

$163.90 +2.80%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

$48.9M

#1584 by earnings

Shares outstanding

56,435,621

Latest filing cover page

P/E ratio

189.2

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#12Apogee TherapeuticsAPGE$10.2B
#13Krystal BiotechKRYS$9.66B
#14RepligenRGEN$9.25B
#15Kymera TherapeuticsKYMR$8.94B
#16QiagenQGEN$8.72B

Where these numbers come from

Share counts and financials for Repligen are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.